Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.

Naloxone 1.8 mg nasal spray (Nyxoid®, Mundipharma) is a single dose solution licensed in adults and adolescents aged 14 years and over. It is indicated for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both nonmedical and healthcare settings.

This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.